EUVIMEDEUVIMED entdecken
Crossref

Implications of Ozempic and Other GLP-1 Receptor Agonists for Facial Plastic Surgeons

Clinton D Humphrey, Anna C Lawrence iD

Facial Plastic Surgery · 2023-12 · 39 (06) · 719-721

DOI: 10.1055/a-2148-6321 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Facial Plastic Surgery, online erschienen am 29.08.2023. Verfasst von Clinton D Humphrey und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, University of Kansas School of Medicine, Kansas City, Kansas. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Surgeons. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity is a growing global health concern. Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Ozempic, have emerged as potential treatments. GLP-1 receptor agonists regulate appetite and can promote weight loss. Some GLP-1 receptor agonists, though Food and Drug Administration (FDA)-approved for diabetes, are also used off-label for weight loss alone. Rapid weight and fat loss with these medications can lead to what has been called “Ozempic Face” on social media and in the lay press, where facial volume and fat are depleted, resulting in wrinkles and sagging skin. Prescribers rarely counsel patients about the potential impact on the face, and the plastic surgery community faces a challenge in managing the facial changes associated with rapid weight loss. Dermal fillers, skin tightening techniques, and surgical interventions are useful for both restoration of facial volume and to manage excess skin. Discontinuation of GLP-1 receptor agonists should be considered prior to general anesthesia due to delayed gastric emptying while on these medications. As the popularity of GLP-1 receptor agonists grows, facial plastic surgeons must be aware of both the impact on facial appearance and perioperative considerations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2SurgeonsUnited StatesHumansHypoglycemic AgentsGlucagon-Like Peptide 1Weight LossSemaglutide

Substanzen

Hypoglycemic AgentsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, University of Kansas School of Medicine, Kansas City, Kansas.

ORCID-Profile: Anna C Lawrence

Zitieren

APA

Humphrey, C. D., & Lawrence, A. C. (2023). Implications of Ozempic and Other GLP-1 Receptor Agonists for Facial Plastic Surgeons. Facial Plastic Surgery, 39(06), 719-721. https://doi.org/10.1055/a-2148-6321

Vancouver

Humphrey CD, Lawrence AC. Implications of Ozempic and Other GLP-1 Receptor Agonists for Facial Plastic Surgeons. Facial Plastic Surgery. 2023;39(06):719-721. doi:10.1055/a-2148-6321

BibTeX
@article{Humphrey2023,
  author = {Humphrey, Clinton D and Lawrence, Anna C},
  title = {Implications of Ozempic and Other GLP-1 Receptor Agonists for Facial Plastic Surgeons},
  journal = {Facial Plastic Surgery},
  year = {2023},
  volume = {39},
  number = {06},
  pages = {719--721},
  doi = {10.1055/a-2148-6321}
}
Kostenlos starten →